Dextromethorphan and Quinidine Combination for Heroin Detoxification

REFERENCES

• Gonzalez G, Oliveto A, Kosten T R. Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother. 2004; 5: 713–725
   PubMed Web of Science ®Google Scholar
• Bisaga A, Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend. 2000; 59: 1–15
   PubMed Web of Science ®Google Scholar
• Bisaga A, Comer S D, Ward A S, Popik P, Kleber H D, Fischman M W. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl). 2001; 157: 1–10
   PubMed Web of Science ®Google Scholar
• Netzer R, Pflimlin P, Trube G. Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur J Pharmacol. 1993; 238: 209–216
   PubMed Web of Science ®Google Scholar
• Bem J L, Peck R. Dextromethorphan. An overview of safety issues. Drug Saf. 1992; 7: 190–199
   PubMed Web of Science ®Google Scholar
• Bisaga A, Gianelli P, Popik P. Opiate withdrawal with dextromethorphan. Am J Psychiatry 1997; 154: 584
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Dahl M L, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002; 53: 111–122
   PubMed Web of Science ®Google Scholar
• Akerele E O, Levin F, Nunes E, Brady R, Kleber H. Effects of HIV triple therapy on methadone levels. Am J Addict. 2002; 11: 308–314
   PubMed Web of Science ®Google Scholar
• Steinberg G K, Bell T E, Yenari M A. Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. J Neurosurg. 1996; 84: 860–866
   PubMedGoogle Scholar
• Wiley J L, Harvey S A, Balster R L, Nicholson K L. Affinity and specificity of N-methyl-D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats. Psychopharmacology (Berl). 2003; 165: 378–385
   Google Scholar
• Albers G W, Atkinson R P, Kelley R E, Rosenbaum D M. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Detrophan Study Group. Stroke 1995; 26: 254–258
   PubMed Web of Science ®Google Scholar
• Pope L E, Khalil M H, Berg J E, Stiles M, Yakatan G J, Sellers E M. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol. 2004; 44: 1132–1142
   PubMed Web of Science ®Google Scholar
• Brooks B R, Thisted R A, Appel S H, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004; 63: 1364–1370
   PubMed Web of Science ®Google Scholar
• Panitch H S, Thisted R A, Smith R A, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006; 59: 780–787
   PubMed Web of Science ®Google Scholar
• Thisted R A, Klaff L, Schwartz S L, et al. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study. Clin Ther. 2006; 28: 1607–1618
   PubMed Web of Science ®Google Scholar
• Himmelsbach C. The morphine abstinence syndrome: its nature and treatment. Ann Intern Med. 1941; 15: 829–839
   Google Scholar
• Koyuncuoglu H. The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. Int J Clin Pharmacol Ther. 1995; 33: 13–19
   PubMed Web of Science ®Google Scholar
• Koyuncuoglu H, Saydam B. The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine. Int J Clin Pharmacol Ther. 1990; 28: 147–152
   Google Scholar
• Farzin D. Modification of naloxone-induced withdrawal signs by dextromethorphan in morphine-dependent mice. Eur J Pharmacol. 1999; 377: 35–42
   PubMed Web of Science ®Google Scholar
• Koyuncuoglu H, Gungor M, Sagduyu H, Aricioglu F. Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats. Pharmacol Biochem Behav. 1990; 35: 829–832
   Google Scholar
• Manning B H, Mao J, Frenk H, Price D D, Mayer D J. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain. 1996; 67: 79–88
   PubMed Web of Science ®Google Scholar
• Zhu H, Jenab S, Jones K L, Inturrisi C E. The clinically available NMDA receptor antagonist dextromethorphan attenuates acute morphine withdrawal in the neonatal rat. Brain Res Rev. 2003; 142: 209–213
   Google Scholar
• Rosen M I, McMahon T J, Woods S W, Pearsall H R, Kosten T R. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. Eur J Pharmacol. 1996; 307: 251–257
   PubMed Web of Science ®Google Scholar
• Kazis A, Kimiskidis V, Niopas I. Pharmacokinetics of dextromethorphan and dextrorphan in epileptic patients. Acta Neurol Scand. 1996; 93: 94–98
   Google Scholar